Convalescent plasma in Covid-19: Possible mechanisms of action
The Author(s). Published by Elsevier B.V. -- Autoimmunity Reviews
DOI 10.1016/j.autrev.2020.102554
  1. Coronavirus
  2. COVID-19
  3. SARS-Cov-2
  4. Convalescent plasma
  5. Cytokines
  6. Intravenous immunoglobulins
  7. Neutralizing antibodies
  8. ACE-2 receptor
  9. 2019-nCoV, 2019 novel coronavirus
  10. ACE-2, Angiotensin converting enzyme-2
  11. ADE, Antibody-dependent enhancement
  12. BAFF, B cell–activating factor
  13. BCR, B-cell receptor
  14. COVID-19, Coronavirus disease 2019
  15. CP, Convalescent plasma
  16. DCs, Dendritic cells
  17. E, Envelope
  18. HIV, Human immunodeficiency virus
  19. ICU, Intensive care unit
  20. IgG, Immunoglobulin G
  21. IgM, Immunoglobulin M
  22. IVIg, Intravenous immunoglobulin
  23. M, Membrane
  24. MERS, Middle East respiratory syndrome
  25. MERS-CoV, MERS coronavirus
  26. N, Nucleoprotein
  27. NAbs, Neutralizing antibodies
  28. NAT, Nucleic acid test
  29. S1-RBD, Spike1-receptor binding protein
  30. SARS, Severe acute respiratory syndrome coronavirus
  31. SARS-CoV, SARS coronavirus.


      Coronavirus disease 19 (COVID-19) is an emerging viral threat with major repercussions for public health.
      There is not specific treatment for COVID-19.
      Convalescent plasma (CP) emerges as the first option of management for hospitalized patients with COVID-19.
      Transference of neutralizing antibodies helps to control COVID-19 infection and modulates inflammatory response.
      Other plasma components may enhance the antiviral and anti-inflammatory properties of CP.